

































Sirtuin proteins are protein deacetylases that contribute 
to the regulation of metabolism, stress responses, and 
aging processes [1-3]. They form class III of the protein 
deacetylase superfamily and hydrolyze one nico-
tinamide adenine dinucleotide (NAD
+) cosubstrate for 
each protein lysine side chain they deacetylate [4]. The 
seven mammalian Sirtuins (Sirt1-7) show different 
intracellular localization [5] and deacetylate different 
sets of substrate proteins. Sirt1 locates to the nucleus 
and regulates, e.g., transcription factors such as p53 and 
PGC-1α [1, 6]. Sirt6 and Sirt7 are also nuclear 
isoforms; Sirt7 regulates RNA polymerase I [7] and can 
deacetylate p53 [8], whereas Sirt6 deacetylates histones 
and regulates DNA stability and repair [9-11]. Sirt2 
mainly resides in the cytosol where it can deacetylate α-
tubulin [12]. Sirt3, 4, and 5 are located in 
mitochondria [5, 13]. Sirt3 appears to regulate a large 
set  of  metabolic enzymes,  whereas only  one  physio- 
 
 
                                                   
































logical Sirt5 substrate is known, carbamoylphosphate 
synthetase I [13-19]. Sirt4 is the only mammalian 
Sirtuin without known deacetylation substrate. Instead, 
Sirt4 was shown to ADP-ribosylate – a second type of 
reaction that can be catalyzed by Sirtuins – glutamate 
dehydrogenase [20].  
 
Sirtuin isoforms contribute to various key aspects of 
metabolic regulation, disease pathologies, and aging [1, 
21]. They are thus considered attractive therapeutic 
targets for diseases such as cancer and neuro-
degenerative disorders [22, 23], which has spurred 
interest in the mechanisms of Sirtuin catalysis and 
regulation and in small-molecule regulators for in vivo 
studies and therapy [22]. Inhibition of Sirt1 was shown 
to sensitize cells for DNA-damaging cancer therapeutics 
[24], and inhibition of Sirt1 and Sirt2 can itself decrease 
tumor growth [25, 26]. A variety of Sirtuin activating 
and inhibiting small molecules has thus been  described  
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low or has not been tested. The widely used inhibitor 
sirtinol (1; Figure 1), for example, has an IC50 of 38 μM 
against Sirt2 in an in vitro assay, shows only ~3-fold 
weaker potency against Sirt1, and no data have been 
reported for its effect on other isoforms [23, 27, 28]. For 
Sirt1, EX-527 (2; Figure 1) was described as potent 
inhibitor with an IC50 of ~0.1 μM, and about two orders 
of magnitude lower potency against Sirt2 and Sirt3 and 
no effect against Sirt5, whereas no data are available for 
Sirt4, 6, and 7 [29]. Several more Sirtuin inhibitors have 
been described, but most of them resemble sirtinol, with 
reported IC50 in the higher μM range, comparable 
potencies against several isoforms, and no data for other 
isoforms [23, 30].  
 
Crystal structures of the catalytic cores of bacterial and 
yeast Sirtuins as well as of mammalian Sirt2, 3, 5, and 6 
reveal a conserved overall structure [31]. They contain a 
large Rossmann fold domain and a small, structurally 
more variable Zn
2+-binding domain. The substrates, 
NAD
+ and the acetyllysine side chain, enter the active 
































mains, and the acetyl group then appears to be 
transferred via a 1’-O-alkylamidate reaction inter-
mediate [4]. For several Sirtuin inhibitors, the lack of 
pronounced isoform specificity might be due to their 
potential binding to the pocket for the NAD
+ 
cosubstrate common to all Sirtuin isoforms. Sirtuins 
have different protein targets, however, even if they are 
colocalized, like Sirt3 and 5 in mitochondria [13]. 
Although they show no strict sequence specificity, 
Sirtuins display residue preferences around the 
deacetylation site [32-34], and the polypeptide binding 
pocket thus should enable isoforms-specific contacts for 
inhibition. A mechanism-based, peptide-derived 
inhibitor indeed showed an IC50 of 4 μM for Sirt1, and 
~17-fold and >77-fold lower potency against Sirt2 and 
Sirt3, respectively [35], indicating the peptide binding 
pocket as a promising target site. Interaction details 
with this and other inhibitors remain to be resolved, 
however, as the only inhibitor complex structure (other 
than complexes with non-specific NAD
+ analogues) is 
the Sirt5 complex with suramin, a non-specific Sirt1/2 
inhibitor partially occupying the NAD
+ and peptide 























































































































































Hit  no.  Sirt2  Sirt3 Sirt5 Sirt6 
1  23128 (CSC6
a)  63875 (CSC15)  95609 (n.t.
b) 51535  (CSC14) 
2  115448 (CSC27)  234766 (CSC34)  371878 (n.t.)  299137 (CSC36) 
3  13987 (n.t.)  13728 (CSC5)  282058 (CSC35)  74702 (CSC17) 
4  11241 (CSC1)  94820 (CSC20)  74702 (CSC17)  13987 (n.t.) 
5  74702 (CSC17)  13726 (CSC4)  105550 (CSC25)  94820 (CSC20) 
6  99550 (CSC24)  99543 (CSC23)  122140 (CSC29)  12363 (CSC3) 
7  128609 (CSC31)  95609 (n.t.)  135371 (CSC33)  79050 (CSC18) 
8  299137 (CSC36)  343227 (n.t.)  13987 (n.t.)  13728 (CSC5) 
9  90318 (CSC19)  23128 (CSC6)  95090 (CSC21)  135371 (CSC33) 
10  94820 (CSC20)  26645 (CSC8)  125252 (CSC30)  23128 (CSC6) 
11  12339 (CSC2)  79050 (CSC18)  300545 (CSC37)  63875 (CSC15) 
12  111326 (CSC26)  99550 (CSC24)  13728 (CSC5)  37245 (CSC12) 
13  402959 (CSC40)  132230 (CSC32)  23128 (CSC6)  371878 (n.t.) 
14  35949(CSC11)  35049 (CSC9)  36806 (n.t.)  13726 (CSC4) 
15  234766 (CSC34)  35489 (CSC10)  128609 (CSC31)  23217 (CSC7) 
16  309883 (CSC38)  74702 (CSC17)  119886 (CSC28)  39863 (CSC13) 
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Sirtuin/inhibitor complexes, more and more structures 
of different Sirtuin isoforms reveal their subtle 
differences. Here, we describe a structure-based 
approach for identifying novel, isoform-specific 
inhibitors for human Sirtuins. Using crystal structures of 
human Sirt2, 3, 5, and 6, we identified potential ligands 
for the peptide binding grove through a docking screen 
with a small molecule library. Characterization of the 
docking hits in in vitro assays reveal two potent, Sirt2-
specific compounds as well as a target site apparently 
enabling isoform specificity and additional compound 
scaffolds for further development, demonstrating the 
power of this approach for the development of specific 




Identification of candidate compounds through a 
docking screen 
 
Despite the physiological and therapeutic importance of 
Sirtuins [22], there is a paucity of potent, isoform-
specific inhibitors [23, 30]. For the identification of 
novel Sirtuin inhibitor classes, we used the available 
crystal structures of human Sirt2 (PDB entry 1J8F)[37], 
Sirt3 (3GLS)[38], Sirt5 (2NYR)[36], and Sirt6 
(3K35)[39] in docking screens. To avoid compounds 
blocking the NAD
+ binding site, which is similar in 
different Sirtuin isoforms, we used complexes of the 
four Sirtuins with the NAD
+-fragment ADP-ribose as 
receptor structures. Complexes were generated by 
transferring ADP-ribose from the experimental 
Sirt6/ADP-ribose structure to the other structures based 
on a superposition of the enzymes. The vacant space in 
the docking target site, defined as a cube centered 
around C1’ of the ADP-ribose, thus corresponds to the 
pocket for recognition of the isoform-specific protein 
substrates and thus should allow isoforms-specific 
contacts. 
 
For identifying potential ligands, we then docked the 
1990 structurally diverse compounds of the National 
Cancer Institute (NCI) diversity set 
(http://www.dtp.nci.nih.gov) to the target sites of the 
four Sirtuins/NAD
+ complexes. Despite some overlap 
between the hit lists, most of the compounds on top of 
the list for each isoform differed from the other 
isoforms (Table 1, 2; Supplementary Table 1). This 
result suggests that the chosen receptor sites indeed 
posses isoforms-specific structural features pronounced 
enough to be distinguishable for a docking approach, 
and thus for the identification of isoform-discriminating 
ligands. 
 
In vitro testing of docking hits reveals non-specific, 
semi-specific, and Sirt2-specific inhibitors 
 
To evaluate the inhibitory potency and specificity of the 
identified potential ligands, we selected the top ten to 
seventeen hits of all four docking runs, resulting in 40 
different compounds after removing NCS compounds 
13987, 95609, 371878, and 343227, which we 
previously found to be incompatible with our assay. 
These compounds were then tested in in vitro activity 
assays for their effects against each of the four Sirtuin 
isoforms, Sirt2, 3, 5, and 6 (Figure 2a, Table 2). The 
experiments showed that two compounds were 
incompatible with the assay, and yielded varying types 
of results for the remaining 38 compounds. In total, 20 
compounds showed significant inhibitory effects (>25 
% loss of activity) on one or several isoforms at the 100 
μM compound concentration used, whereas 18 
compounds had no such effect (Table 3). The high hit 
rate of 53 % for the general ability to inhibit Sirtuins is 
comparable to hit rates in other library docking screens 
[40, 41] and indicates a successful enrichment of true 
ligands on top of the hit lists. Of the 20 inhibitory 
compounds, six (30 % of the inhibitory ones) inhibited 
more than one isoform; five of the six (25 %) were 
“semi-specific”, i.e. inhibited more than one but not all 
isoforms tested, whereas one compound (CSC1) 
behaved as a “broad-band” Sirtuin inhibitor that 
inhibited all isoforms. Surprisingly, all 14 compounds 
with a significant inhibitory effect against only one 
isoform were selective for Sirt2, yielding a panel of 
potential lead structures for the development of Sirt2-
specific inhibitors. For Sirt3, 5, and 6, for which no 
specific modulators have yet been described, the five 
“semi-specific” inhibitors could still be interesting as 
leads (see below), especially the three compounds that 
just affect two isoforms. 
 
The specific compounds 3 and 4 show high potency 
against Sirt2 
 
Of the tested compounds, 14 showed specificity for 
Sirt2 based on our selection criterion of >25 % 
inhibition. From this panel of potential leads for the 
development of Sirt2-specific inhibitors, we picked the 
two compounds that showed the largest effects in the 
screen for further characterization. The compounds 3-
hydroxyestra-1,3,5(10)-trien-17-yl 3-phenylpropanoate 
(CSC8, 3; Figure 1) and 1,11a,13a-trimethyl-8-phenyl-
2,3,3a, 3b,4,5, 5a, 6, 11, 11a, 11b, 12, 13, 13a-tetradeca-
hydro-1H-cyclopenta[5,6]naphtho[1,2-g]quinazolin-1-ol 
(CSC13, 4; Figure 1) inhibited Sirt2 to ~80 % in the 
screen, but had little or no effect on the other Sirtuin 
isoforms tested. A further characterization in dose- 
 
   

















































































































activity,  red  Sirt3,  yellow  Sirt5,  and  blue  Sirt6.  CSC5  and  40  were  not
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concentration of 100 μM revealed IC50 values of 4.8 ± 
0.5 μM for 3 and 9.7 ± 1.5 μM for 4 (Figure 2b,c). We 
also tested the effects of 3 and 4, respectively, on the in 
vitro activity of Sirt1 (Figure 2d). Both compounds had 
only a weak inhibitory effect at a concentration of 100 
μM. Thus, both compounds are potent Sirt2 inhibitors 
with high isoform specificity.  
 
It is noteworthy that 3 and 4 share considerable portions 
of their scaffolds (Figure 1). They both feature a steroid 
moiety, but modified at opposite ends; 3 is an estradiol 
with a bulky substituent at the 17-hydroxyl group, 
whereas  4 contains a steroid scaffold with a 2-benzyl 
pyrimidine fused to the A ring. Thus, the steroid scaffold 
is an attractive lead structure for the development at least 
of Sirt2-specific compounds, and even larger modifica-
tions are possible, which should enable to avoid signify-




































Proposed binding orientation and molecular 
determinants for specificity 
 
In order to gain insights into potential molecular 
determinants of compound specificity and starting 
points for compound variations in future development 
efforts, we analyzed the docking positions and 
orientations of 3 and 4 and differences in the respective 
binding sites between the Sirtuin isoforms (Figure 
3a,b,c). In the model of the Sirt2 complex with 3 
(Figure 3a), hydrophobic interactions are observed 
between the estradiol ring system and several side 
chains (Phe96, Leu107, Phe119 and Ile169) of a large, 
hydrophobic cavity (formed by the interacting residues 
and Ala85, Tyr104, and Ile118) extending into the small 
Sirtuin Zn
2+-domain. In addition, the hydroxyl-group of 
3 forms hydrogen bonds to the side chain of Asn168, 
the backbone of Gln167, and the α-phosphate-group of 
ADP-ribose.  
 
For the Sirt2 complex with 4 (Figure 3b), two 
orientations were predicted with similar frequencies 
and binding energies. Orientation 1 shows only 
hydrophobic interactions between the sterol ring 
system and the hydrophobic pocket around Phe119 
described above, whereas orientation 2 covers the 
same site, allowing less optimized hydrophobic 
interactions but in addition hydrogen bridges to 
Asn168 and Gln167 as observed in the model of the 
Sirt2 complex with 3.  
 
A comparison of the corresponding pockets in the four 
structurally characterized Sirtuin isoforms reveals that 
Sirt3, 5, and 6 have narrower pockets than Sirt2 (Figure 
3c). In Sirt3, the hydrophobic residues are moved 
toward each other, closing the binding pocket compared 
to Sirt2. In Sirt5 and 6, there are bulkier residues (in 
both cases two Trp) lining the hydrophobic pocket, 
again making it smaller, and the protein backbone is 
partly moved into the pocket either from top-left (Sirt5) 
or bottom-right (Sirt6). These differences likely 
contribute to the observation in our screen, as well as 
from analysis of available compounds, that specific 
inhibition seems easier to achieve for Sirt2 than for 
Sirt3, 5, and 6. It suggests that for specific inhibition of 
the latter isoforms, smaller scaffolds should be favored 
(see below). For improvement of Sirt2 inhibitors, the 
docking model suggests that the hydrophobic 
substituent at position 17 of the sterol scaffold of 3 
should be further extended. Such additional groups 
should contain polar functions, which could interact 
with polar protein groups or solvent at the pocket 
entrance and which would improve the solubility and 









modeled  Sirt2/ADP‐ribose  complex  and  4.  Two  orientations
representing  poses  about  equally  favored  by  the  docking
program  are  shown.  Residues  suggested  to  be  involved  in
binding interactions are shown as sticks and labeled. (c) Overlay



















































































































Figure 4. Effects  of  compounds  3  and  4  on 
Sirt2‐dependent  α‐tubulin deacetylation and 





and  anti‐tubulin  antibody,  respectively.  The  bars 
show the signal ratios, indicating that the tubulin‐
deacetylating  activity  of  Sirt2  is  lowered  by  the 
addition of compound 4. (b) Splitomicin (8) is an 
established inhibitor for yeast Sir2, and HR73 (9) 
and  the  tetracyclic  pyrimidinedione  10  for 
mammalian  Sirt1.  11,  12,  and  13  are  identified 
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1,3(2H)-dione (CSC16, 5) is also a steroid-based 
compound (Table 2), but despite of its similarity, 
especially to 3, it had no effect on any of the tested 
Sirtuin enzymes. According to the structures and 
docking models, the binding pocket is too narrow for 
the compound in Sirt3 and 5, so that it was docked with 
low binding energy to the surface of the respective 
Sirtuin. In Sirt2 and 6, 5 could be docked in the 
hydrophobic pocket, but in both cases in a 
disadvantageous position, with carbonyl- and hydroxyl-
oxygens of the compound near hydrophobic patches.  
 
Semi-specific compounds as inhibitor scaffolds and 
as lead compounds 
 
It is noticeable that for all compounds of our screen 
with an inhibitory effect, Sirt2 is either the only isoform 
affected or belongs to the group of isoforms that is 
inhibited. Most likely, this result is due to the larger 
hydrophobic binding pocket identified from analysis of 
the docking models (see above). However, compounds 
that inhibit Sirt2 and another isoform might still be 
developable into compounds specific for the other 
isoforms. The very large, hydrophobic compounds 
CSC1, CSC6, CSC14, and CSC27 (Table 2) likely 
cover non-specifically many large cavities and are 
unlikely to yield good pharmacological compounds, but 
CSC10 (6) and CSC21 (7; Table 2) appear promising. 
Due to its size, howeer, the essential parts of 7 should be 
determined in a structure-activity study before further 
development. 6, in contrast, resembles compounds such 
as splitomicin (8), HR73 (9), and 10 (Figure 4), which 
were reported as micromolar inhibitors for a Sirtuin (8 for 
yeast Sir2 [42], 9 and 10 for human Sirt1 [26, 43]), but 
which were not tested against most mammalian isoforms. 
No structural data are available for Sirtuin complexes 
with any of these compounds, but our structure 
comparison (see above) suggests that smaller scaffolds 
might enable these compounds to exploit the site where 3 
was docked, which appears not to be accessible for 
bulkier compounds in Sirt3, 5, and 6. These scaffolds 
should thus be considered for the development of the first 
inhibitors specific for these Sirtuin isoforms. Considering 
that  6 already shows different potencies against the 
isoforms tested here (Figure 2), its phenanthrene and 
isochinoline moieties as well as similar groups should be 
further evaluated for specific Sirtuin inhibition.  
 
Activity of the novel Sirt2 inhibitors in a 
physiological system 
 
Our novel compounds 3 and 4 are potent and specific 
Sirt2 inhibitors in vitro, and we next tested the effect of 
4 (compound 3 is likely to be sensitive to esterase 
activity in lysates) on the Sirt2-dependent deacetylation 
of an in vivo substrate in a physiological environment. 
The acetylation levels of the Sirt2-deacetylation site 
Lys40 in α-tubulin [12] were analyzed in HEK cell 
lysates by using an acetyl-Lys40 specific antibody 
(Figure 4a). Adding Sirt2 strongly decreased the level 
of tubulin Lys40 acetylation in the lysate when no 
inhibitor was present, and the deacetylation effect was 
decreased in presence of 100 μM compound 4. Thus, 
compound  4 is an inhibitor for the physiological α-
tubulin deacetylation activity of Sirt2. 
 
We further examined the likely suitability of 3 and 4 for 
in vivo use by applying analyses comparable to 
Lipinski’s rule of five (using the molinspiration server 
at www.molinspiration.com). Both compounds appear 
generally suitable as pharmacological compounds, 
except for their lack of sufficient polar groups, leading 
to an unfavourable partitition coefficient. Compound 3 
is further predicted to likely act as a ligand for nuclear 
receptors. In fact, the sterol ester 3 might be hydrolyzed 
in a physiological environment and thus generate a 
generic steroid receptor ligand. Compound 4, instead, 
was not predicted to bind to nuclear receptors, most 
likely due to the larger deviation from the steroid 
scaffold. Testing on HEK cells revealed very high 
cytotoxicity for 3 (compound 4 showed a smaller effect 
but possibly due to partial precipitation under these 
conditions), but it remains to be clarified whether the 
corresponding mechanism is based on Sirt2 inhibition. 
However, 3 and 4 are potent and isoforms-specific Sirt2 
inhibitors, and especially 4 appears promising for the 
development of side effect-free Sirt2 inhibitors, with 
adding suitable polar groups to this scaffold being a first 




The roles of Sirtuins in central physiological processes 
and as drug targets have led to great demand for specific 
inhibitors for research and therapy [22, 23]. Available 
compounds often feature limited or unknown 
specificities and mostly high micromolar potencies, and 
surprisingly little structural information is available for 
Sirtuin/inhibitor complexes, which could be used for 
rational improvement. However, we show here that the 
increasing number of Sirtuin isoform structures in non-
inhibited state [31] allow the structure-based 
identification of novel, isoform-specific inhibitor 
classes. A previous docking study on Sirt2 [44], the 
only structurally characterized mammalian isoform at 
that time, yielded only two Sirt2 inhibitors with IC50 
values below 100 μM (57 and 74 μM, respectively), and 
their isoform specificities were not evaluated. The lower 
hit rate and affinities than in our study might have 
   
www.impactaging.com                   859                                    AGING,    September 2011, Vol.3 No.9several reasons. Tervo et al. used a structure as docking 
receptor that had undergone a molecular dynamics 
(MD) simulation, resulting in major deviations from the 
experimental structure, which might not well represent 
the major conformations of the protein. To take protein 
flexibility into account, using several structures - 
representing different conformers – simultaneously, or 
simulating flexible side-chains during docking are now 
often used approaches [45]. The first option is not yet 
possible for most Sirtuins due to the lack of such 
multiple structures, and it appears that ignoring receptor 
flexibility is in fact a viable strategy for identifying 
Sirtuin inhibitors, at least for Sirt2. To take side chain 
flexibility into account, however, might be an approach 
for identifying compounds specific for the other 
isoforms studied here, Sirt3, 5, and 6 [40]. A further 
difference to our approach was that several potential 
inhibitors were not considered for experimental testing 
due to missing features assumed to be important for 
inhibition, which might have removed potent 
compounds. Also, a different docking software (GOLD) 
and compound database were used (Maybridge). The 
Mabridge database, being much larger than the NCI 
diversity set used here, is unlikely to be a bottleneck, 































programs differ in their performance depending on the 
interaction type, e.g. small versus large and 
hydrophobicversus hydrophilic ligands [40]. Binding of 
the most potent inhibitors identified appears to be 
dominated by hydrophobic interactions with a large 
cavity, which was previously observed not to give best 
results with GOLD [40]. Finally, we used a receptor 
with partially occupied NAD
+ binding site. Thereby, we 
tried to avoid to obtain compounds binding to the NAD
+ 
binding site present in similar form in all Sirtuins, as 
well as other NAD-dependent enzymes, likely resulting 
in little specificity. This approach further takes into 
account that interactions with the bound NAD
+ can 
contribute to inhibitor affinity. The docking models 
obtained indeed indicate that NAD
+ forms part of the 
bottom of the pocket likely occupied by the inhibitors. 
However, instead of mainly occupying the peptide 
binding cleft, the compounds were preferentially docked 
perpendicular to this cleft, extending into a hydrophobic 
pocket in the Zn
2+ domain. If this binding orientation is 
confirmed by structural studies, then fusing to 
compounds such as 6 smaller substituents exploiting the 
isoforms specific features of the peptide binding grooves 
might be an attractive approach for further improvement 








































































































































































































































































































































































































































































































Even though the NCI diversity set is supposed to 
represent a varying scaffold repertoire, it contains a 
number of series of structurally related compounds.  
 
Interestingly, a series of related combinations of benzyl 
and naphtyl systems connected through a methylen and 
a methanimine bridge was identified in our screen 
(CSC22-24, Figure 4), and showed differences in the 
effects on the four Sirtuins tested (Figure 2a). All 
compounds inhibited only Sirt2, but CSC23 (11) had a 
larger effect than CSC22 (12) or CSC24 (13). They 
show a certain similarity to 1 (Sirtinol [28]; Figure 1) 
and the closely related Salermide [46], established 
Sirtuin inhibitors with some preference for Sirt2 over 
Sirt1 [23]. The observed differences suggest that further 
evaluating such combinations of three linked ring 
systems might have potential for further development of 
specific and potent inhibitors. Most promising for Sirt2 
inhibition, however, appear the steroid-based 
compounds 3 and 4, which should be further developed 
to overcome some disadvantages, such as limited 
polarity and solubility. Further, 3 should be sensitive to 
cellular esterase activities and is likely to act as a ligand 
for nuclear receptors, whereas 4 shows larger deviation 
from the steroid scaffold and thus might be the more 
promising lead for the development of side effect-free 
Sirtuin inhibitors. Several known Sirtuin inhibitors also 




























Sirt2-selective pyrimidinedione 6 [26] and Splitomicin 
(7; [42]), which slightly resemble the A-C ring system 
of steroids and thus might exploit the same binding site. 
Attractive approaches for further development of these 
known and our novel inhibitors would be their rational 
modification, but the lack of structural information for 
these and most other Sirtuin inhibitors hinders such 
approaches. The putative binding pocket identified here, 
however, might already allow identifying improved 
Sirtuin inhibitors by screening of larger virtual libraries 
with more drug-like compounds, even before the 
anxiously awaited structural information on Sirtuin 
inhibitor complexes become available. 
 
Improved compounds, derived from our Sirt2 inhibitors 
or identified through docking more drug-like 
compounds to their putative binding site, would be 
helpful for functional studies and promising for therapy. 
Acetylation of tubulin, a known Sirt2 deacetylation 
substrate [12], increases the stability of microtubule, 
and a reduction of tubulin acetylation in neurons has 
been reported for individuals with Alzheimer’s disease 
[47]. Sirt2 inhibition could thus be an approach for 
therapy of this and other neurodegenerative diseases, 
such as Parkinson’s disease, where Sirt2 inhibition was 
shown to prevent death of dopaminergic cells [48]. Sirt2 
further contributes to regulation of cell cycle 
progression [49], and although details of its function 
   
www.impactaging.com                    865                                  AGING, September 2011, Vol.3 No.9seem to vary in different cancers, inhibition of Sirt2 
seems to be a viable approach for destroying tumor cells 
[25, 26]. The other isoforms studied here might also be 
interesting drug targets, such as the mitochondrial forms 
Sirt3 and 5 for metabolic and aging-related diseases due 
to their role in regulating metabolic enzymes and stress-
responses [21, 50]. Our data indicate that compounds 
















































exploiting the tighter pockets of these isoforms 
corresponding to the predicted binding site for 3 and 4. 
The binding site, however, is so far speculative, and the 
tighter conformation crystallized might just be one of 
several in solution, so that more information, such as 
Sirtuin/inhibitor complex structures or extensive 
structure-activity-relationship studies will be necessary 













































Compound  (NCS)  Sirt2 Sirt3 Sirt5 Sirt6 
CSC1 (11241)  inhibition
a  inhibition inhibition inhibition 
CSC2  (12339)  inhibition  --- --- --- 
CSC3  (12363)  --- --- --- --- 
CSC4  (13726)  inhibition  --- --- --- 
CSC5 (13728)  n.c.
b  n.c. n.c. n.c. 
CSC6  (23128)  inhibition  --- --- inhibition 
CSC7  (23217)  inhibition  --- --- --- 
CSC8  (26645)  inhibition  --- --- --- 
CSC9 (35049)  inhibition  ---  activation
c --- 
CSC10 (35489)  inhibition  inhibition  ---  inhibition 
CSC11  (35949)  --- --- --- --- 
CSC12  (37245)  --- --- --- --- 
CSC13  (39863)  inhibition  --- --- --- 
CSC14 (51535)  inhibition  ---  inhibition  --- 
CSC15  (63875)  --- --- --- --- 
CSC16  (72254)  --- --- --- --- 
CSC17  (74702)  --- --- --- --- 
CSC18  (79050)  --- --- --- --- 
CSC19  (90318)  --- --- --- --- 
CSC20  (94820)  --- --- --- --- 
   











































Target Preparation and virtual ligand screening. For the 
docking study the crystal structures of human Sirt2 
(PDB entry 1J8F), Sirt3 (3GLS), Sirt5 (2NYR), and 
Sirt6 (3K35) were used. In all structures, water 
molecules and ligands were removed except for ADP-
ribose from the Sirt6 crystal structure, which was 
modeled in all other structures in the NAD
+-binding site 














































atoms were then added to the complex, and Kollman 
charges and AutoDock 4 atom type assigned by using 
AutoDockTools (http://autodock.scripps.edu/resources/ 
adt). The docking site was defined as a box of 60 Å x 58 
Å x 58 Å and was centered around the C1’ atom of the 
ADP-ribose. For the virtual screen, the 1990 
compounds of the NCI diversity set 
(http://www.dtp.nci.nih.gov) representing different 
scaffolds were docked into the Sirtuin receptor sites 
with AutoDock Vina [51]. The ligands were used in a 
 
CSC21 (95090)  inhibition  ---  inhibition  inhibition 
CSC22  (99515)  inhibition  --- --- --- 
CSC23  (99543)  inhibition  --- --- --- 
CSC24  (99550)  inhibition  --- --- --- 
CSC25  (105550)  --- --- --- --- 
CSC26  (111326)  --- --- --- --- 
CSC27  (115448)  inhibition  --- --- inhibition 
CSC28  (119886)  inhibition  --- --- activation 
CSC29  (122140)  --- --- --- --- 
CSC30  (125252)  --- --- --- --- 
CSC31  (128609)  --- --- --- --- 
CSC32  (132230)  inhibition  --- --- --- 
CSC33 (135371)  ---  ---  activation  activation 
CSC34  (234766)  inhibition  --- --- activation 
CSC35  (282058)  --- --- --- --- 
CSC36  (299137)  --- --- --- --- 
CSC37  (300545)  inhibition  --- --- --- 
CSC38 (309883)  inhibition  ---  activation  activation 
CSC39  (351123)  --- --- --- --- 
CSC40  (402959)  n.c. n.c. n.c. n.c. 
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charges, and assigned AutoDock 4 atom types available 
from http://autodock.scripps.edu/resources/databases.  
For each Sirtuin (2, 3, 5, 6) the 10 compounds with the 
best simulated binding energies in the docking study 
were further used for activity assays. Figures of 
structural models were generated with Pymol 
(http://www.pymol.org/). 
Chemicals. The most promising docking hits were 
obtained from the NCI (http://www.dtp.nci.nih.gov). All 
other chemicals were obtained from Sigma (Saint Louis, 
USA) if not stated differently.  
 
Cloning, recombinant expression, and purification of 
human Sirt1, 2, 3, 5 and 6. Human gene fragment 
comprising Sirt2 residues 34-356, Sirt3 residues 114-
399, Sirt5 residues 34-302, and Sirt6 residues 13-308 
were PCR amplified from full length cDNA clones and 
cloned into pET151/D-TOPO (Invitrogen, Carlsbad, 
USA), resulting in constructs with N-terminal his-tag 
and a linker comprising a TEV protease cleavage site. 
The full-length human Sirt1 gene was PCR amplified 
from a cDNA clone and inserted into vector pET15b 
(Merck Biosciences, Darmstadt, Germany) resulting in 
a thrombin cleavable his-tag at the N-terminus. 
 
Sirt3 was expressed in E. coli and purified via Ni-NTA 
and size exclusion chromatography as described 
elsewhere [18], and Sirt5 according to the protocol of 
Schuetz et al. [36]. Sirt1 was expressed and purified as 
described for Sirt3, except that after affinity purification 
the protein was passed through a Superdex200 gel 
filtration column (GE Healthcare, New Jersy, USA) 
equilibrated in Buffer A (25 mM HEPES, pH 7.5, 100 
mM KCl, 2 mM DTT), followed by HiTrapQ (GE 
Healthcare, Waukesha, WI, USA) anion exchange 
chromatography. The protein was bound to the HiTrapQ 
column in buffer A and eluted in a gradient to buffer A 
supplemented with 400 mM KCl. Fractions were 
analyzed by SDS-PAGE, and the Sirt1 fractions were 
pooled and transferred into buffer A using a NAP 
column (GE Healthcare). 
 
The Sirt2 construct was expressed in E. coli Rosetta2 
cells (Merck) in LB/Ampicillin/Chloramphenicol 
medium. Cells were grown at 37 °C, and expression 
induced at an OD600 of 0.6-0.8 for 4 h with 0.5 mM 
IPTG. Harvested cells were resuspended in buffer A (50 
mM Tris/HCl pH 7.8, 200 mM NaCl, 2 mM DTT), 
disrupted with a Sonifier, and cell debris removed by 40 
min centrifugation at 4 °C, 18000 rpm in a HFA22.50 
rotor. The supernatant was supplemented with 10 mM 
imidazole and incubated with Ni-NTA resin for 1 h at 4 
°C. The resin was washed in a column with 10 volumes 
buffer B (50 mM Tris/HCl, pH 7.8, 500 mM NaCl, 2 
mM DTT) and 10 volumes buffer A supplemented with 
10 mM imidazol, and eluted with 50 mM Tris/HCl, pH 
7.8, 20 mM NaCl, 60 mM imidazol, 2 mM DTT. The 
protein was concentrated in an amicon unit (Millipore, 
Billerica, USA) and digested over night at 4 °C with 
TEV-protease. The protease was removed from cleaved 
Sirt2 by incubation with Ni-NTA resin for 1 h at 4 °C. 
The protein was concentrated, 1:5 diluted with 50 mM 
Tris/HCl, pH 7.8, and applied to a HiTrap Q anion 
exchange column (GE Healthcare) equilibrated with 50 
mM Tris/HCl, pH 7.8, 50 mM NaCl, 2 mM DTT and 
eluted with a gradient (20 column volumes) to 50 mM 
Tris/HCl, pH 7.8, 1 M NaCl, 2 mM DTT. Sirt2 was then 
applied to a Superdex200 gel filtration column (GE 
Healthcare) equilibrated in 20 mM Tris/HCl, pH 7.8, 
150 mM NaCl, 2 mM DTT. The eluted protein was 
analyzed by SDS-PAGE, re-concentrated, and shock-
frozen in liquid nitrogen for storage at -80 °C. 
 
The Sirt6 construct was expressed in E. coli Rosetta2 
cells and purified through NiNTA affinity 
chromatography, TEV cleavage, and ion exchange 
chromatography as described for Sirt2, except that cells 
were shaken over night at 20 °C after induction, pH7.0 
was used for all buffers, and a HiTrap SP cation 
exchange column (GE Healthcare) was used for ion 
exchange chromatography.  
 
Peptide deacetylation assay. The commercial Fluor-de-
Lys (FdL) assay kits 1 and 2 (Biomol, Plymouth 
Meeting, USA) were used to test the deacetylase 
activity of the four Sirtuins. In both kits the substrate 
derived from p53 is composed of three amino acids, the 
acetyl lysine and a C-terminally attached fluorophor. 
For Sirt2 and 3, FdL-2 peptide (QPK(acetyl-K)) was 
used, and FdL-1 peptide (RHK(acetyl-K)) for Sirt5 and 
Sirt6. All tests were done with 0.1 mM of the respective 
FdL peptide and 0.5 mM NAD
+ as substrates.  
 
NCI compound stocks were prepared by dissolving 
them in DMSO at a concentration of 5 mM. The initial 
screens with all 40 compounds contained 5 µl Sirtuin 
solution (Sirt2/3 0.1 mg/ml stock concentration; Sirt5/6 
1 mg/ml), 1 µl of compound stock (resulting in a 100 
µM end concentration), 15 µl FdL substrate, and assay 
buffer (supplied in the assay kit) to a total volume of 50 
µl. As control reactions, peptide with either the 
compound (without Sirtuin) or with Sirtuin and DMSO 
instead of compound were measured. After starting the 
reactions by adding the FdL substrate, assays were 
incubated for 30 min at 37 °C. Subsequently, 50 µl of a 
10 mg/ml trypsin stock (“Developer solution”) were 
added and the reactions were incubated for 45 min at 
room temperature. Fluorescence values were measured 
in a fluorometric plate reader with excitation at 360 nm 
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with the control reaction (same compound, but without 
Sirtuin). For dose-response curves, concentrations of 
the compounds were varied (0.1, 0.5, 2, 10, 50, 150 
and 500 µM final concentrations in the assay) by 
diluting stock solution in DMSO so that constant 
volumes were added, except for the highest 
concentration, where a higher final DMSO 
concentration had to be accepted. 
 
All measurements shown are averages of duplicates 
(screen) or triplicates (dose-response curves), and 
representatives of at least two independent replications. 
Error bars indicate standard deviations. 
 
Tubulin deacetylation assay. HEK 293T cells were 
grown in DMEM medium (PAN Biotech) 
supplemented with 10% fetal bovine serum (PAN 
Biotech) at 37°C and 5% CO2. Cells were harvested, 
washed with PBS, and resuspended and lysed using 
hypotonic buffer (10mM Tris-HCl, pH 8.0, 3mM KCl) 
supplemented with protease inhibitors cocktail. Cell 
debris was removed by centrifugation (10,000g, 10 
minutes) at 4°C, and 50µl reaction were prepared with 
identical amounts of cell lysate and either 100 μM 
compound 4, 1 μg Sirt2, or both. All samples further 
contained the same amount of DMSO (to account for 
the solvent of the stock of 4) and 25 mM HEPES (pH 
7.5; to compensate for the solvent of the NAD
+ stock). 
20 µg total protein was then loaded on a gel for 
blotting with the monoclonal anti-acetylated tubulin 
antibody (Sigma), and 10 µg total protein for the blot 
with anti-tubulin antibody (Epitomics, Burlingame, 
CA, USA). Proteins were blotted to polyvinyl-
idenfluorid membrane, incubated with primary (2 h) 
and then secondary antibodies at room temperature(1h; 
anti-Mouse IR Dye 680LT and goat anti-Rabbit IR 
Dye 680LT (Li-Cor Biosciences, Lincoln, NE, USA), 
respectively), and the blots were scanned in the 700 
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Supplementary Table 1, showing the hit positions of the 
40 experimentally tested compounds in the docking 




































































































Compound  (NCS)  Sirt2 Sirt3 Sirt5 Sirt6 
CSC1 (11241)  4  ---  ---  --- 
CSC2 (12339)  11  ---  ---  --- 
CSC3  (12363)  --- --- --- 6 
CSC4  (13726)  --- 5  --- --- 
CSC5  (13728)  --- 3  --- 8 
CSC6 (23128)  1  9  ---  10 
CSC7  (23217)  --- --- --- 15 
CSC8  (26645)  --- 10 --- --- 
CSC9  (35049)  --- 14 --- --- 
CSC10  (35489)  --- 15 --- --- 
CSC11 (35949)  14  ---  ---  --- 
CSC12  (37245)  --- --- --- 12 
CSC13  (39863)  --- --- --- 16 
CSC14  (51535)  --- --- --- 1 
CSC15  (63875)  --- 1  --- --- 
CSC16  (72254)  --- --- --- 17 
CSC17  (74702)  5 ---  4 3 
CSC18  (79050)  --- --- --- 7 
CSC19 (90318)  9  ---  ---  --- 
CSC20 (94820)  10  4  ---  5 
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CSC21 (95090)  ---  ---  9  --- 
CSC22 (99515)  ---  17  ---  --- 
CSC23 (99543)  ---  6  ---  --- 
CSC24  (99550)  6  --- --- --- 
CSC25 (105550)  ---  ---  5  --- 
CSC26  (111326)  12 --- --- --- 
CSC27  (115448)  2  --- --- --- 
CSC28 (119886)  ---  ---  16  --- 
CSC29 (122140)  ---  ---  6  --- 
CSC30 (125252)  ---  ---  10  --- 
CSC31  (128609)  7  --- --- --- 
CSC32 (132230)  ---  13  ---  --- 
CSC33 (135371)  ---  ---  7  9 
CSC34 (234766)  ---  2  ---  --- 
CSC35 (282058)  ---  ---  3  --- 
CSC36  (299137)  8  --- --- 2 
CSC37 (300545)  ---  ---  11  --- 
CSC38  (309883)  16 --- --- --- 
CSC39 (351123)  ---  ---  17  --- 
CSC40  (402959)  13 --- --- --- 
 